Overview Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer Status: Completed Trial end date: 2015-03-01 Target enrollment: Participant gender: Summary The study hypothesis is that metronomic treatment is more efficient than standard treatment. Phase: Phase 2 Details Lead Sponsor: University of AarhusCollaborator: Pierre Fabre LaboratoriesTreatments: CapecitabineVinblastineVinorelbine